NTRC announces IND approval for the TTK/PLK dual inhibitor BAL0891 in its collaboration with Swiss pharmaceutical company Basilea
Oss, 17 December 2021 – NTRC, a Dutch precision medicine company that is specialized in discovery and development of innovative kinase inhibitors to treat cancer patients, today announces that the U.S. Food and Drug [...]
TDO is a novel therapeutic target for Parkinson’s disease
February 22, 2021: A new article on the pharmacological validation of TDO as a target for Parkinson's disease is now online in The FEBS Journal (Perez-Pardo et al., 2021). The figure [...]
Tryptophan-metabolizing enzymes in cancer immunology
January 28, 2021: A new article on the role of tryptophan-metabolizing enzymes in cancer immunology is now online in Frontiers in Immunology (Grobben et al., 2021). The figure shows a co-culture assay of IDO1-overexpressing [...]
Clustering analysis of recently approved kinase inhibitors presented at Discovery on Target 2020 – Virtual
September 14, 2020: Hierarchical clustering of kinase inhibitors based on their IC50 profiles in the Oncolines™ panel. Names of approved kinase inhibitors are given in red. Clustering analysis of recently [...]
Novel screening assay for Arginase-1 inhibitors published in SLAS Discovery
May 18, 2020: Dose response curves of reference inhibitors in the Arginase Gold™ assay (left) and inhibitory constant (Ki) as function of reaction time (right). Adapted from Grobben et al. (2020). [...]
Dose- and Effect-based Drug Combination Methods Merged into One Approach
Left: Dose-based synergy results from a decrease in dose to achieve the same effect, quantified with the CI value. Right: Effect-based synergy results from an increase in the maximum effect, quantified by Bliss [...]
NTRC Participates in Alpe d’HuZes 2020 to Raise Money for Cancer Research
NTRC thanks our sponsors for the cycling event Alpe d’HuZes. Special thanks to our shirt sponsors: Pivot Park, Miltenyi Biotec, Glycostem, Perkin Elmer, Hulshof Kroonen & Groen. NTRC Participates in [...]
New Structural Insights into Arginase-1, a Target for Cancer Immunotherapy
X-ray protein crystal structure of human Arginase-1 with the small molecule inhibitor CB-1158. New structural insights into Arginase-1, a target for Cancer Immunotherapy Oss, November, 29th, 2019 – NTRC scientists [...]
NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer
NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer Oss, March, 27th, 2019 – NTRC and Radboudumc Nijmegen (The Netherlands) are developing a platform to predict the response of [...]
Effective discovery of synergistic combinations by computational approaches
In silico approach for the discovery of synergistic combinations Oss, March 19, 2019 - Successful cancer therapies are often based on drug combinations to halt cancer growth and prevent resistance mechanisms. A good way [...]
NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018
Arginase-1 (Arg-1) is an important drug target for cancer immunotherapy. Expression of Arg-1 by tumour-infiltrating myeloid derived suppressor cells induces local L-arginine depletion, which results in reduced T-cell and natural killer cell proliferation. Despite increased [...]
New predictive drug response biomarkers for approved kinase inhibitors
Oss, November, 02, 2018 – Kinase inhibitors illustrate the successful translation of basic scientific knowledge of cancer into new targeted therapies. Selecting the right patient population based on the occurrence of specific cancer driver events [...]
Target residence time-guided lead optimization at the European Pharma Summit in Berlin
Oss, November, 10th, 2017 – At GTC Bio’s European Pharma Summit to be held in Berlin on 16 and 17 November, Dr. Guido Zaman will present on NTRC’s TTK drug discovery program in a scientific [...]
NTRC’s key TTK kinase inhibitor patent granted in US
Oss, September, 19th , 2017 – NTRC, a biopharmaceutical company focused on the discovery and development of innovative precision medicines for the treatment of cancer, today announced that the United States Patent and Trademarks Office [...]
NTRC publishes an association of CTNNB1 mutant status and increased cancer cell line sensitivity to TTK inhibitors
Normal 0 21 false false false NL X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:Standaardtabel; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} Oss, July, 27th, 2017 [...]
NTRC expands Oncolines™ cell line panel to 102 cell lines
Oss, June 22nd 2017 – Today NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines. Oncolines™ are proliferation assays on a panel of genetically well-characterized cancer [...]
NTRC publishes target residence time-guided optimization of TTK inhibitors
Oss, May 22nd 2017 - This week, NTRC published results from its TTK (Mps1) drug discovery programme in the Journal of Molecular Biology. TTK is a promising new drug target for the treatment of aggressive [...]
New study in Oncotarget shows that stable aneuploid cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
Oss, March, 16th, 2017 – In a research article which appeared online today in Oncotarget, NTRC scientists, in collaboration with Prof. Dr. René Medema from the Netherlands Cancer Institute (NKI), show that stable aneuploid tumor [...]
Kinetic parameters of 80 kinase inhibitors available online through the Journal of Molecular Biology
Oss, January, 2nd, 2017 – NTRC has made available the kinetic data of 80 kinase inhibitors on their targets in a research article in the Journal of Molecular Biology. This is the largest data base [...]
Structural insight into the function of TDO in healthy aging
Oss, Groningen, December, 23rd, 2016 – Researchers from the European Research Institute for the Biology of Aging (ERIBA) University of Groningen, the Netherlands) in collaboration with the Netherlands Translational Research Center B.V. have identified an [...]
NTRC presents on TTK kinase program at AACR conference
Oss, April, 8th, 2016 – At the AACR 2016 conference, to be held in New Orleans next week, Jos de Man, Senior Investigator Chemistry at NTRC, will present on the unique binding mode of NTRC’s [...]
NTRC has identified IDO1 inhibitors with best-in-class properties by screening at the European Lead Factory
Oss, December, 9th, 2015 – NTRC today announced that they have identified a series of IDO1 inhibitors with best-in-class properties by screening at the European Lead Factory (ELF). IDO1 is an important target in cancer [...]
NTRC and Vipergen receive Eurostars support for cancer immunotherapy research
Oss, Copenhagen, December 04th, 2015 - NTRC (Netherlands) and Vipergen ApS (Denmark) announced that they have received support from the EUREKA Eurostars Programme for their research on the identification of novel drug candidates for cancer [...]
NTRC presents at Discovery on Target conference in Boston
Guido Zaman and Suzanne van Gerwen will attend the Discovery on Target conference, that will be held in Boston (USA) from September 21st to 24th. On Thursday September 24th at 12.10 p.m., Guido Zaman will [...]
Novel therapeutic target proposed to increase the efficacy of taxane chemotherapy
Oss - Amsterdam, July 10th, 2015 – Researchers from the Netherlands Cancer Institute (NKI), in collaboration with NTRC and University Medical Center Utrecht, have discovered that inhibition of the protein kinase TTK, a protein involved [...]
Whole genome doubling causes multidrug resistance
Oss, July 7th, 2015 – In a new study in Cell Cycle, researchers from the Max Planck Institute and NTRC show that doubling of the whole genome of human cancer cells provides resistance to a [...]
NFK GreenScreen™ and TTK program presented at EACR-AACR conference in Florence
Guido Zaman and Suzanne van Gerwen will attend the EACR-AACR Special Conference, that will be held in Florence (Italy) from June 20th to 23rd. On Monday, June 22nd, two posters will be presented: one on [...]
Selective targeting of cancer driver genes by combinations of existing drugs published in PLOS ONE
Oss, May, 27th, 2015 – NTRC scientists have discovered new combinations of existing drugs to selectively target difficult-to-drug cancer genes, such as MYC and KRAS. The results of these studies have been published today in [...]
TTK drug discovery program presented at Protein Kinases conference in Berlin
Guido Zaman and Suzanne van Gerwen will attend the 10th “Protein Kinases in Drug Discovery” conference, that will be held in Berlin on May 7th and 8th. On Friday, May 8th, Guido Zaman will present [...]
ResidenceTimer™ and TTK drug discovery program presented at Drug Discovery Chemistry meeting in San Diego
Rogier Buijsman will present and chair one of the sessions of the 6th Kinase Inhibitor Chemistry symposium, which is part of the 10th Annual Drug Discovery Chemistry conference, that will be held in San Diego [...]
NTRC receives Michael J. Fox Foundation support for TDO program for Parkinson’s disease
Oss, April, 3rd, 2015 – NTRC today announced that it has received an award from The Michael J. Fox Foundation For Parkinson’s Research to conduct research on inhibitors of tryptophan-2,3-dioxygenase (TDO), a new treatment option [...]
TTK program and SynergyFinder™ presented at TAT 2015 conference in Paris
NTRC is exhibiting sponsor of the 13th international conference on Targeted Anticancer Therapies (TAT), that we be held in Paris (France) from March 2nd to 4th. NTRC Services will participate in the commercial exhibition and [...]
NTRC receives qualified hit series for TDO from the European Lead Factory
Oss, The Netherlands, 18th February 2015 – NTRC today announced that it has received a collection of fifty small molecule inhibitors for TDO from the European Lead Factory (ELF). TDO (Tryptophan 2,3-dioxygenase) is an important [...]
NTRC launches assay for mouse IDO1 and mouse TDO activity
Cancer immunotherapy aims at the stimulation of the body’s immune system to fight cancer. The T-cell immune response against cancer cells is dampened by the activity of the enzymes indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase [...]
NTRC and Utrecht University start collaborative research project on Parkinson’s disease
Oss, January, 5th, 2014 – Parkinson’s disease is a degenerative disease of the central nervous system. Researchers from NTRC and the group of Dr. Aletta Kraneveld from the Utrecht University Institute of Pharmaceutical Sciences bundle [...]
NTRC will present at 8th International Protein Kinase Inhibitors conference in Warsaw
Guido Zaman and Suzanne van Gerwen will attend and present at the 8th International Conference on Protein Kinase Inhibitors (IPK2014) held in Warsaw, Poland, from September 21st to 25th. The distinguished list of speakers at [...]
NTRC publishes high-throughput screening assay for IDO1 and TDO in Journal of Biomolecular Screening
Immunotherapy is one of the recent advances in cancer treatment. Cancer immunotherapy makes use of the body’s immune system to help fight cancer. The amino acid tryptophan is an important regulator of the immune system [...]
NTRC will present at Discovery Partnerships Conference in Berlin
Guido Zaman will attend IQPC’s Discovery Partnerships Conference held in Berlin on May 19th and 20th. On Tuesday, May 20th, at 4.00 p.m., Guido Zaman will give a presentation on NTRC’s collaborations and drug discovery [...]
NTRC will present at Protein Kinases in Drug Discovery Conference in Berlin
Joost Uitdehaag will attend GTC’s Protein Kinases in Drug Discovery Conference held in Berlin on May 8th and 9th. On Friday, May 9th, at 11.45 p.m., Joost Uitdehaag will give a presentation on the profiling [...]
NTRC launches new service ResidenceTimer™ at Drug Discovery Chemistry conference in San Diego
Rogier Buijsman and Suzanne van Gerwen will attend CHI’s 9th Drug Discovery Chemistry conference held in San Diego from April 23rd to 25th. On Thursday, April 24th, Rogier Buijsman will chair the afternoon session, entitled [...]
NTRC publishes Oncolines™ profiles of all marketed small molecule kinase inhibitor drugs in PLOS ONE
Oss, March 20th, 2014 – Over the past decade targeted therapies have significantly increased the efficiency of cancer therapy. They bring great benefit to patients because they improve survival rates with much less side effects [...]
NTRC will present at Drug Discovery Innovations Conference 2014
NTRC will present at Drug Discovery Innovations Conference 2014 in Berlin. Date: March 19th, 2014 Session: Cell based assays, phenotypic screening and pioneering technologies www.informa-ls.com/event/DDI2014
NTRC will present at Frontiers in Medicinal Chemistry 2014 in Tübingen.
NTRC will present at the GDCH Frontiers in Medicinal Chemistry 2014 in Tübingen. Date: March 18th, 2014 Session: Inflammation www.gdch.de
NTRC to partner with European centers of excellence in training network for next generation cancer researchers
Oss, October 14th, 2014 - Together with nine leading universities and research institutes in Europe and two other companies, Netherlands Translational Research Center B.V. (NTRC) will train eleven young cancer researchers in the field of [...]
NTRC obtains exclusive license for Merck kinase candidate compounds
Oss - 13 November 2012 - Netherlands Translational Research Center B.V. (NTRC) today announced that it has entered into an exclusive license agreement with Merck & Co, Inc., through its affiliate MSD Oss B.V. Under [...]
NTRC starts at the Life Sciences Park Oss
Oss – 6 June 2012 - Netherlands Translational Research Center B.V. (NTRC) starts operations at the Life Sciences Park Oss, after successful closing its first round of financing. With the financial support of the Brabant [...]